**Table E1**. Potential predictors of an adequate EBUS sample for PD-L1 testing.

|  |  |  |  |
| --- | --- | --- | --- |
| **Variable** | **Univariable analysis** | | |
| **p-value** | **OR** | **95% CI** |
| **NSCLC subtype (adenocarcinoma vs. other)** | 0.894 | 0.90 | (0.18-4.50) |
| **Disease stage (I-II vs. III-IV)** | 0.101 | 0.23 | (0.04-1.33) |
| **Site of sample (hilar vs. mediastinal)** | 0.275 | 0.48 | (0.13-1.79) |
| **Number of needle passes (continuous variable)** | 0.177 | 0.72 | (0.44-1.16) |
| **Number of needle passes (>3 vs. ≤3)** | 0.279 | 0.46 | (0.11-1.88) |
| **Availability of ROSE** | 0.461 | 0.43 | (0.05-4.07) |